No Data
Earnings Not Telling The Story For Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278)
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Xiamen Amoytop Biotech (688278.SH): donated 9 million yuan to the China Hepatitis Prevention and Treatment Fund.
On March 7, 2023, Xiamen Amoytop Biotech (688278.SH) announced that the company's ninth Board of Directors held its sixth meeting on March 7, 2025, unanimously approving the proposal for external donations. The company decided to donate 9 million yuan to the China Hepatitis Prevention and Control Foundation (hereinafter referred to as the "Foundation"), for the public welfare project aimed at controlling high-risk populations related to hepatitis B virus (HBV) and liver cancer.
Is Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Latest Stock Performance A Reflection Of Its Financial Health?
Tebao Biotech: Tepo Biotech: 2024 Annual Results Report Announcement
Tebao Biotech: 2024 Annual Results Report Announcement
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention Today